Table 1.
Cohort demographics
| Full cohort | Cytokine groups | |||||||
|---|---|---|---|---|---|---|---|---|
| Demographic | Control (n = 75) | Schizophrenia (n = 90) | Difference | Con low (n = 46) | Con elevated (n = 22) | SCZ low (n = 43) | SCZ elevated (n = 39) | Difference |
| Age in years (median + range) | 29 (20–50) | 35 (20–51) | U = 2339, p < 0.001 | 28 (20–50) | 31 (22–49) | 35 (20–51) | 35 (20–50) | H(3) = 13.41, p < 0.01 |
| Gender | 36 F:39 M | 37 F:53 M | χ2 = 0.787, p = 0.375 | 20 F:26 M | 13 F:9 M | 19 F:24 M | 16F:23 M | χ2 = 2.059, p = 0.560 |
| RIN ± SD | 7.89 ± 1.11 | 7.61 ± 1.00 | U = 2666.5, p = 0.028 | 8.23 ± 0.60 | 7.79 ± 1.26 | 7.81 ± 0.67 | 7.42 ± 1.18 | H(3) = 8.55, p = 0.036 |
| Age of onset (in years and range) | 22.7 (12–46) | 22.5 (12–46) | 22.8 (16–32) | U = 920, p = 0.448 | ||||
| Duration of illness in years | 13.0 ± 7.51 | 12.7 (3–29) | 13.8 (2–31) | U = 932.5, p = 0.382 | ||||
| PANSS positive | 15.2 ± 4.56 | 15.0 ± 4.49 | 15.2 ± 4.43 | t(80) = −0.187, p = 0.852 | ||||
| PANSS negative | 14.4 ± 6.13 | 14.8 ± 5.70 | 13.7 ± 6.55 | U = 714, p = 0.247 | ||||
| PANSS general | 30.7 ± 8.80 | 30.3 ± 8.1 | 30.7 ± 9.3 | U = 829, p = 0.930 | ||||
| PANSS total | 60.3 ± 16.70 | 60.2 ± 15.4 | 59.6 ± 17.7 | U = 796, p = 0.693 | ||||
| Mean daily chlorpromazine equivalent dose (mg) | 558 ± 474 | 546 ± 489 | 569 ± 501 | U = 834, p = 0.967 | ||||
| Body mass index | 30.9 ± 6.46 | 30.4 ± 6.55 | 30.9 ± 6.41 | t(69) = −0.341, p = 0.734 | ||||
Notes: All values, except age, are mean ± SD standard deviation, PANSS Positive and Negative Symptom Scale, RIN RNA integrity number